Low-dose Colchicine for CABG Graft Failure Prevention

Prior treatment

• Severe valvular heart disease requiring concomitant or staged valvular surgery;
• Drug or alcohol abuse;
• Other immunosuppressive therapies already in existence or planned;
• Strong CYP3A4 or P-glycoprotein inhibitors (such as cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) have been used and no other alternative drugs can be used.

Other illness

• History of non-skin cancer in the past 3 years;
• Inflammatory bowel disease or chronic diarrhea;
• Neuromuscular diseases or non-transient creatine kinase levels greater than 3 times the upper limit of the normal range (except those associated with myocardial infarction);
• History of clear or suspected colchicine allergy;

Lab values

• Clinically significant non-transient (At least 2 laboratory tests) blood abnormalities (Hemoglobin \<100g/L or hematocrit \< 30% or \> 52% or white blood cell count \< 3×109/L or platelet count \< 100×109/L);
• Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m² (based on the CKDEPI formula);
• Serum alanine aminotransferase and/or aspartate aminotransferase levels greater than 2 times the upper limit of the normal range, accompanied by serum total bilirubin levels greater than 2 times the upper limit of the normal range or severe liver disease with coagulation disorders (INR\>1.5) (except for elevated glutamic oxalacetic transaminase associated with myocardial infarction);

Other

• Decline in cognitive function due to inability to perform basic activities of daily living independently;
• Other causes require long-term colchicine treatment;

• Be male or female, aged 18 years or older;
• Within 3 days after successful isolated coronary artery bypass grafting (CABG);
• Sign informed consent;